title: Course of blood pressure within the first 12 h of hypertensive urgencies.
abstract: OBJECTIVE
  To evaluate the course of blood pressure within 12 h of a hypertensive urgency with or without oral antihypertensive treatment prior to discharge of patients from hospital.
  
  
  METHODS
  A prospective, double-blinded, placebo-controlled and randomized clinical trial.
  
  
  METHODS
  Department of Emergency Medicine in a 2000-bed inner city hospital.
  
  
  METHODS
  Forty patients successfully treated for a hypertensive urgency with intravenous administration of urapidil.
  
  
  METHODS
  We administered 60 mg urapidil orally or placebo prior to discharge of patients from hospital and evaluated the course of blood pressure within 12 h of the urgency by use of an ambulatory blood pressure measurement unit.
  
  
  METHODS
  Mean systolic and diastolic blood pressures within the first 12 h of a hypertensive urgency and the number of hypertensive and hypotensive episodes.
  
  
  RESULTS
  Mean systolic and diastolic blood pressures were significantly lower in members of the urapidil group than they were in members of the placebo group (132 +/- 14 versus 147 +/- 18 mmHg, P = 0.003; 79 +/- 12 versus 87 +/- 14 mmHg, P = 0.047, respectively). The number of hypotensive episodes was similar for these two groups (three versus one, P = 0.32), whereas the number of hypertensive episodes was significantly lower for the urapidil group (13 versus 34, P = 0.001).
  
  
  CONCLUSIONS
  Oral medication with urapidil prior to discharge results in lower overall blood pressure levels and reduces the risk of hypertensive episodes recurring within 12 h of a hypertensive urgency. Therefore, we recommend this therapeutic approach for patients with hypertensive urgencies, who are treated with an intravenous antihypertensive drug.
authors.affiliation: Department of Emergency Medicine, University of Vienna, Austria. michael.hirschl@akh-wien.ac.at
authors.forename: M M
authors.initials: MM
authors.lastname: Hirschl
authors.forename: H
authors.initials: H
authors.lastname: Herkner
authors.forename: A
authors.initials: A
authors.lastname: Bur
authors.forename: C
authors.initials: C
authors.lastname: Woisetschläger
authors.forename: G
authors.initials: G
authors.lastname: Gamper
authors.forename: M
authors.initials: M
authors.lastname: Frossard
authors.forename: A N
authors.initials: AN
authors.lastname: Laggner
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D004311:Double-Blind Method; D004630:Emergencies; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology*; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies; D013997:Time Factors
chemical_list: D000959:Antihypertensive Agents; D010879:Piperazines; C015568:urapidil